A comprehensive list of individual human medicinal products will be implemented on January 1, 2025, as part of the new arrangements established by the Windsor Framework. This framework aims to streamline regulatory processes and enhance the movement of goods between the UK and the EU, particularly in the pharmaceutical sector.
The introduction of these category lists signifies a pivotal shift in how pharmaceutical products are regulated and categorized, potentially affecting compliance requirements for manufacturers and suppliers. With the new arrangements, companies will need to ensure their products align with the updated classifications to avoid disruptions in market access and to maintain adherence to regulatory standards.
As the industry prepares for these changes, stakeholders across regulatory, QA/QC, and CMC sectors must closely monitor developments to adapt their strategies accordingly. The implications of the Windsor Framework could reshape sourcing practices and portfolio management, necessitating a proactive approach to ensure continued compliance and market competitiveness.
Get started today with Solo access →
